Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC
Ability to understand and willingness to sign a written informed consent document.
Aged at least 18 years old.
Histologically or cytologically confirmed locally advanced or metastatic NSCLC (stage IIIB~IV).
EGFR mutations, including exon 19 deletion and exon 21 L858R.
Previous treatment with MET inhibitors or HGF-targeted therapy.
There are mutations of ALK or ROS1.
Have symptomatic and neurologically unstable central nervous system (CNS) metastases or CNS disease that requires increased steroid doses for control.
Pregnant or nursing women.